These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 25371406)

  • 1. Lack of utility of SDHB mutation testing in adrenergic metastatic phaeochromocytoma.
    Sue M; Martucci V; Frey F; Lenders JM; Timmers HJ; Peczkowska M; Prejbisz A; Swantje B; Bornstein SR; Arlt W; Fassnacht M; Beuschlein F; Robledo M; Pacak K; Eisenhofer G
    Eur J Endocrinol; 2015 Feb; 172(2):89-95. PubMed ID: 25371406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis.
    van Nederveen FH; Gaal J; Favier J; Korpershoek E; Oldenburg RA; de Bruyn EM; Sleddens HF; Derkx P; Rivière J; Dannenberg H; Petri BJ; Komminoth P; Pacak K; Hop WC; Pollard PJ; Mannelli M; Bayley JP; Perren A; Niemann S; Verhofstad AA; de Bruïne AP; Maher ER; Tissier F; Méatchi T; Badoual C; Bertherat J; Amar L; Alataki D; Van Marck E; Ferrau F; François J; de Herder WW; Peeters MP; van Linge A; Lenders JW; Gimenez-Roqueplo AP; de Krijger RR; Dinjens WN
    Lancet Oncol; 2009 Aug; 10(8):764-71. PubMed ID: 19576851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status.
    Eisenhofer G; Lenders JW; Siegert G; Bornstein SR; Friberg P; Milosevic D; Mannelli M; Linehan WM; Adams K; Timmers HJ; Pacak K
    Eur J Cancer; 2012 Jul; 48(11):1739-49. PubMed ID: 22036874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations.
    Zelinka T; Timmers HJ; Kozupa A; Chen CC; Carrasquillo JA; Reynolds JC; Ling A; Eisenhofer G; Lazúrová I; Adams KT; Whatley MA; Widimsky J; Pacak K
    Endocr Relat Cancer; 2008 Mar; 15(1):311-23. PubMed ID: 18310297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contrasting clinical manifestations of SDHB and VHL associated chromaffin tumours.
    Srirangalingam U; Khoo B; Walker L; MacDonald F; Skelly RH; George E; Spooner D; Johnston LB; Monson JP; Grossman AB; Drake WM; Akker SA; Pollard PJ; Plowman N; Avril N; Berney DM; Burrin JM; Reznek RH; Kumar VK; Maher ER; Chew SL
    Endocr Relat Cancer; 2009 Jun; 16(2):515-25. PubMed ID: 19208735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel succinate dehydrogenase subunit B (SDHB) mutations in familial phaeochromocytomas and paragangliomas, but an absence of somatic SDHB mutations in sporadic phaeochromocytomas.
    Benn DE; Croxson MS; Tucker K; Bambach CP; Richardson AL; Delbridge L; Pullan PT; Hammond J; Marsh DJ; Robinson BG
    Oncogene; 2003 Mar; 22(9):1358-64. PubMed ID: 12618761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolomics, machine learning and immunohistochemistry to predict succinate dehydrogenase mutational status in phaeochromocytomas and paragangliomas.
    Wallace PW; Conrad C; Brückmann S; Pang Y; Caleiras E; Murakami M; Korpershoek E; Zhuang Z; Rapizzi E; Kroiss M; Gudziol V; Timmers HJ; Mannelli M; Pietzsch J; Beuschlein F; Pacak K; Robledo M; Klink B; Peitzsch M; Gill AJ; Tischler AS; de Krijger RR; Papathomas T; Aust D; Eisenhofer G; Richter S
    J Pathol; 2020 Aug; 251(4):378-387. PubMed ID: 32462735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic Deregulation of Protocadherin PCDHGC3 in Pheochromocytomas/Paragangliomas Associated With SDHB Mutations.
    Bernardo-Castiñeira C; Valdés N; Celada L; Martinez ASJ; Sáenz-de-Santa-María I; Bayón GF; Fernández AF; Sierra MI; Fraga MF; Astudillo A; Jiménez-Fonseca P; Rial JC; Hevia MÁ; Turienzo E; Bernardo C; Forga L; Tena I; Molina-Garrido MJ; Cacho L; Villabona C; Serrano T; Scola B; Chirivella I; Del Olmo M; Menéndez CL; Navarro E; Tous M; Vallejo A; Athimulam S; Bancos I; Suarez C; Chiara MD
    J Clin Endocrinol Metab; 2019 Nov; 104(11):5673-5692. PubMed ID: 31216007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of phaeochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants: an international expert Consensus statement.
    Taïeb D; Nölting S; Perrier ND; Fassnacht M; Carrasquillo JA; Grossman AB; Clifton-Bligh R; Wanna GB; Schwam ZG; Amar L; Bourdeau I; Casey RT; Crona J; Deal CL; Del Rivero J; Duh QY; Eisenhofer G; Fojo T; Ghayee HK; Gimenez-Roqueplo AP; Gill AJ; Hicks R; Imperiale A; Jha A; Kerstens MN; de Krijger RR; Lacroix A; Lazurova I; Lin FI; Lussey-Lepoutre C; Maher ER; Mete O; Naruse M; Nilubol N; Robledo M; Sebag F; Shah NS; Tanabe A; Thompson GB; Timmers HJLM; Widimsky J; Young WJ; Meuter L; Lenders JWM; Pacak K
    Nat Rev Endocrinol; 2024 Mar; 20(3):168-184. PubMed ID: 38097671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metastatic Pheochromocytoma and Paraganglioma: Somatostatin Receptor 2 Expression, Genetics, and Therapeutic Responses.
    Fischer A; Kloos S; Maccio U; Friemel J; Remde H; Fassnacht M; Pamporaki C; Eisenhofer G; Timmers HJLM; Robledo M; Fliedner SMJ; Wang K; Maurer J; Reul A; Zitzmann K; Bechmann N; Žygienė G; Richter S; Hantel C; Vetter D; Lehmann K; Mohr H; Pellegata NS; Ullrich M; Pietzsch J; Ziegler CG; Bornstein SR; Kroiss M; Reincke M; Pacak K; Grossman AB; Beuschlein F; Nölting S
    J Clin Endocrinol Metab; 2023 Sep; 108(10):2676-2685. PubMed ID: 36946182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metastatic pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations.
    King KS; Prodanov T; Kantorovich V; Fojo T; Hewitt JK; Zacharin M; Wesley R; Lodish M; Raygada M; Gimenez-Roqueplo AP; McCormack S; Eisenhofer G; Milosevic D; Kebebew E; Stratakis CA; Pacak K
    J Clin Oncol; 2011 Nov; 29(31):4137-42. PubMed ID: 21969497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterisation of an Adult Zebrafish Model for
    Miltenburg JB; Gorissen M; van Outersterp I; Versteeg I; Nowak A; Rodenburg RJ; van Herwaarden AE; Olthaar AJ; Kusters B; Conrad C; Timmers HJLM; Dona M
    Int J Mol Sci; 2024 Jul; 25(13):. PubMed ID: 39000369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The phenotype of
    Niemeijer ND; Rijken JA; Eijkelenkamp K; van der Horst-Schrivers ANA; Kerstens MN; Tops CMJ; van Berkel A; Timmers HJLM; Kunst HPM; Leemans CR; Bisschop PH; Dreijerink KMA; van Dooren MF; Bayley JP; Pereira AM; Jansen JC; Hes FJ; Hensen EF; Corssmit EPM
    Eur J Endocrinol; 2017 Aug; 177(2):115-125. PubMed ID: 28490599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study.
    Schovanek J; Martucci V; Wesley R; Fojo T; Del Rivero J; Huynh T; Adams K; Kebebew E; Frysak Z; Stratakis CA; Pacak K
    BMC Cancer; 2014 Jul; 14():523. PubMed ID: 25048685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters.
    van Berkel A; Rao JU; Lenders JW; Pellegata NS; Kusters B; Piscaer I; Hermus AR; Plantinga TS; Langenhuijsen JF; Vriens D; Janssen MJ; Gotthardt M; Timmers HJ
    J Nucl Med; 2015 Jun; 56(6):839-46. PubMed ID: 25883126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Krebs cycle metabolite profiling for identification and stratification of pheochromocytomas/paragangliomas due to succinate dehydrogenase deficiency.
    Richter S; Peitzsch M; Rapizzi E; Lenders JW; Qin N; de Cubas AA; Schiavi F; Rao JU; Beuschlein F; Quinkler M; Timmers HJ; Opocher G; Mannelli M; Pacak K; Robledo M; Eisenhofer G
    J Clin Endocrinol Metab; 2014 Oct; 99(10):3903-11. PubMed ID: 25014000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma.
    Hadoux J; Favier J; Scoazec JY; Leboulleux S; Al Ghuzlan A; Caramella C; Déandreis D; Borget I; Loriot C; Chougnet C; Letouzé E; Young J; Amar L; Bertherat J; Libé R; Dumont F; Deschamps F; Schlumberger M; Gimenez-Roqueplo AP; Baudin E
    Int J Cancer; 2014 Dec; 135(11):2711-20. PubMed ID: 24752622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age at diagnosis of pheochromocytoma differs according to catecholamine phenotype and tumor location.
    Eisenhofer G; Timmers HJ; Lenders JW; Bornstein SR; Tiebel O; Mannelli M; King KS; Vocke CD; Linehan WM; Bratslavsky G; Pacak K
    J Clin Endocrinol Metab; 2011 Feb; 96(2):375-84. PubMed ID: 21147885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diffusion-weighted imaging (DWI) highlights SDHB-related tumours: A pilot study.
    Tufton N; White G; Drake WM; Sahdev A; Akker SA
    Clin Endocrinol (Oxf); 2019 Jul; 91(1):104-109. PubMed ID: 30934121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. False-negative ¹²³I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease.
    Fonte JS; Robles JF; Chen CC; Reynolds J; Whatley M; Ling A; Mercado-Asis LB; Adams KT; Martucci V; Fojo T; Pacak K
    Endocr Relat Cancer; 2012 Feb; 19(1):83-93. PubMed ID: 22167067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.